A Randomized, Open, Comparative Multicentre Trial of 3 Years Anastrozole Treatment vs. 3 Years no Treatment in Postmenopausal Patients With Breast Cancer Who Have Completed 5 Years Adjuvant Hormone Therapy.
Phase 3
N/A
80 Years
N/A
80 Years
Not Enrolling
Female
Breast Neoplasms
Female
Breast Neoplasms
Trial Information
A Randomized, Open, Comparative Multicentre Trial of 3 Years Anastrozole Treatment vs. 3 Years no Treatment in Postmenopausal Patients With Breast Cancer Who Have Completed 5 Years Adjuvant Hormone Therapy.
Inclusion Criteria:
- No disease recurrence at time of randomization,
- patients with breast cancer after surgery,
- 5 years (+/- 12 months) of prior endocrine therapy
Exclusion Criteria:
- Premenopausal patients,
- unknown or negative receptor status,
- Secondary malignant tumor
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Recurrence-free and overall survival
Principal Investigator
AstraZeneca Austria Medical Director, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
Austria: Federal Ministry for Health and Women
Study ID:
1033AU/0001
NCT ID:
NCT00300508
Start Date:
January 1996
Completion Date:
Related Keywords:
- Breast Neoplasms
- Hormone receptor positive breast cancer
- Breast Neoplasms
- Neoplasms
Name | Location |
|---|
